fda deadline for semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know Novo asks FDA to bar

These costs make treatment inaccessible for many people seeking sustainable weight loss solutions

Medication access concerns drive many transitions, and people report mixed experiences depending on their sources

Just a really great example of tech progress improving living standards in a deep way

These symptoms are usually most intense during the first few weeks of treatment or immediately following a dose increase

Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under limited, legally defined circumstances . On February 21, 2025 , the U.S

See our detailed cost breakdown